Amylyx Pharmaceuticals
Founded Year
2014Stage
IPO | IPOTotal Raised
$205.83MDate of IPO
1/7/2022Market Cap
1.97BStock Price
29.59About Amylyx Pharmaceuticals
Amylyx (NASDAQ: AMLX) is an IND-enabling stage biopharmaceutical company dedicated to providing disease-modifying solutions for neurodegenerative diseases. The company is focused on streamlined clinical development and drug discovery.
Missing:Amylyx Pharmaceuticals'sProduct Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing:Amylyx Pharmaceuticals'sProduct & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Amylyx Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Amylyx Pharmaceuticals is included in1 Expert Collection,includingBiopharma Tech.
Biopharma Tech
1,568 items
Amylyx PharmaceuticalsPatents
Amylyx Pharmaceuticals has filed 18 patents.
The 3 most popular patent topics include:
- Rare diseases
- Calcium channel blockers
- Motor neuron diseases
Application Date |
Grant Date |
Title |
Related Topics |
Status |
|---|---|---|---|---|
|
7/27/2020 |
2/21/2023 |
Hepatology, Pharmaceutical industry, Bile acids, Cholanes, Life sciences industry |
Grant |
Application Date |
7/27/2020 |
|---|---|
Grant Date |
2/21/2023 |
Title |
|
Related Topics |
Hepatology, Pharmaceutical industry, Bile acids, Cholanes, Life sciences industry |
Status |
Grant |
LatestAmylyx PharmaceuticalsNews
Apr 21, 2023
Abata hires Leonard Dragone as CMO Plus: Amylyx gets a head of international markets, and updates from Heron, Breye, Alvotech and more By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst April 20, 2023 7:43 PM UTC Regulatory T cell therapy company Abata Therapeutics Inc. hired Leonard Dragone as CMO, to succeed co-founder and interim CMO Richard Ransohoff. Dragone was CMO at Sonoma Biotherapeutics Inc.; Ransohoff, who will become an adviser to the company, is a venture partner at Third Rock Ventures. Neurodegenerative disease company Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) hired Masako Nakamura as general manager and head of international markets — Asia Pacific and Latin America. Nakamura was SVP, head of Asia at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and held various roles during her decade at the Genzyme Corp. unit of Sanofi (Euronext:SAN; NASDAQ:SNY). ... BCIQ Company Profiles
Amylyx PharmaceuticalsFrequently Asked Questions (FAQ)
When was Amylyx Pharmaceuticals founded?
Amylyx Pharmaceuticals was founded in 2014.
Where is Amylyx Pharmaceuticals's headquarters?
Amylyx Pharmaceuticals's headquarters is located at 43 Thorndike Street, Cambridge.
What is Amylyx Pharmaceuticals's latest funding round?
Amylyx Pharmaceuticals's latest funding round is IPO.
How much did Amylyx Pharmaceuticals raise?
Amylyx Pharmaceuticals raised a total of $205.83M.
Who are the investors of Amylyx Pharmaceuticals?
Investors of Amylyx Pharmaceuticals include Belinda Termeer, Rock Springs Capital, Perceptive Advisors, 5Y Capital, Polaris Founders Capital and 19 more.
Who are Amylyx Pharmaceuticals's competitors?
Competitors of Amylyx Pharmaceuticals include OptoCeutics and 2 more.
Compare Amylyx Pharmaceuticals to Competitors
EnClear Therapies develops a treatment device to stop the progress of neurodegenerative diseases.
OptoCeutics發展醫學光可以備份文件夾e the neuronal activity of Alzheimer's patients and reduce plaque accumulation, which can lead to the development of new medical technologies. The technology is based on known gamma light therapy research, but combines the light in a new way that the flickering is non-perceptible and thus not hindering vision or causing discomfort. The firm was founded in 2018 and is based in Copenhagen, Denmark.
Cava Healthcare is focused on enhancing optimal health by predicting, preventing and alleviating diseases.
Cassava Sciences is clinical-stage biopharmaceutical company focused on neuroscience. It is based in Austin, Texas.
D&D Pharmatech is a healthcare holding company that develops therapeutics for dementia, Alzheimer's disease, and Parkinson's disease.
Disarm Therapeutics is developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration. On October 15th, 2020, Disarm Therapeutics was acquired by Eli Lilly & Co at a valuation of $135M.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.